Tumor Biology

, Volume 36, Issue 8, pp 6433–6443 | Cite as

Inhibition of mdr1 by G-quadruplex oligonucleotides and reversal of paclitaxel resistance in human ovarian cancer cells

  • Biao Wang
  • Shuo Li
  • Xin Meng
  • Hong Shang
  • Yifu Guan
Research Article

Abstract

The expression of ATP-dependent efflux pump P-glycoprotein (P-gp) in cancer cells generally results in multidrug resistance (MDR) to chemotherapeutic drugs, which is the main cause of chemotherapy failure in cancer treatment. The intracellular drug levels could be increased by some MDR reversal agents that inhibited the drug efflux activity of P-gp. The synthesized DNA nucleic acids of G-quadruplex represent a novel and unique class of anti-cancer agents. While there was no report on the roles of DNA G-quadruplex oligonucleotides (GQ-ODNs) in the MDR reversal, the present study was performed to investigate the ability of synthesized GQ-ODNs to reverse P-gp-mediated MDR and its mechanism in paclitaxel (PTX)-resistant SKOV3 (SKOV3/PTX) cells and their sensitive cell lines SKOV3. The ability of GQ-ODNs to reverse drug resistance was evaluated by MTS assay. The results showed that GQ-ODNs can reverse PTX resistance effectively. The potential of GQ-ODNs as reversal agents was evaluated with the nude mice tumor xenograft model and showed that the co-administration of the GQ-ODNs and PTX had better effects and was also more evident than treatment with only PTX. The P-gp expression was assessed by the Western blot; it showed that SKOV3/PTX cells showed highly expressed P-gp protein, while their sensitive cells scarcely showed P-gp. The presence of GQ-ODNs efficiently decreased the P-gp expression, showing that GQ-ODNs could reverse P-gp-mediated MDR by decreasing the expression of P-gp. This study indicated that GQ-ODNs could effectively reverse P-gp-mediated PTX resistance by inhibiting the expression of P-gp and by the co-administration of GQ-ODNs and PTX that could increase the apoptosis of SKOV3/PTX cells. Thus, the synthesized GQ-ODNs may be a potential inhibitor to overcome drug resistance.

Keywords

G-quadruplex P-glycoprotein Paclitaxel Ovarian cancer 

Notes

Acknowledgments

This work was supported by the National Natural Science Foundation of China (No. 81271292 and No. 81371896) and the Natural Science Foundation of Liaoning Province (2013225089).

Conflict of interest

None

References

  1. 1.
    Johnson DH, Paul DM, Hande KR, et al. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol Off J Am Soc Clin Oncol. 1996;14(7):2054–60.CrossRefGoogle Scholar
  2. 2.
    McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334(1):1–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Simpkins F, Belinson JL, Rose PG. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol. 2007;107(1):118–23.CrossRefPubMedGoogle Scholar
  4. 4.
    Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets. 2003;3(1):1–19.CrossRefPubMedGoogle Scholar
  5. 5.
    Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr. 1993;15:55–61.Google Scholar
  6. 6.
    Ford JM, Bruggemann EP, Pastan I, Gottesman MM, Hait WN. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res. 1990;50(6):1748–56.PubMedGoogle Scholar
  7. 7.
    Bellamy WT, Dalton WS. Multidrug resistance in the laboratory and clinic. Adv Clin Chem. 1994;31:1–61.CrossRefPubMedGoogle Scholar
  8. 8.
    Seiden MV, Swenerton KD, Matulonis U, et al. A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol. 2002;86(3):302–10.CrossRefPubMedGoogle Scholar
  9. 9.
    Webba da Silva M. Geometric formalism for DNA quadruplex folding. Chemistry. 2007;13(35):9738–45.CrossRefPubMedGoogle Scholar
  10. 10.
    Huppert JL. Four-stranded nucleic acids: structure, function and targeting of G-quadruplexes. Chem Soc Rev. 2008;37(7):1375–84.CrossRefPubMedGoogle Scholar
  11. 11.
    Balasubramanian S, Neidle S. G-quadruplex nucleic acids as therapeutic targets. Curr Opin Chem Biol. 2009;13(3):345–53.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Agarwal T, Jayaraj G, Pandey SP, Agarwala P, Maiti S. RNA G-quadruplexes: G-quadruplexes with “U” turns. Curr Pharm Des. 2012;18(14):2102–11.CrossRefPubMedGoogle Scholar
  13. 13.
    Wu Y, Brosh Jr RM. G-quadruplex nucleic acids and human disease. FEBS J. 2010;277(17):3470–88.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Huppert JL. Structure, location and interactions of G-quadruplexes. FEBS J. 2010;277(17):3452–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Chaires JB. Human telomeric G-quadruplex: thermodynamic and kinetic studies of telomeric quadruplex stability. FEBS J. 2010;277(5):1098–106.CrossRefPubMedGoogle Scholar
  16. 16.
    Goodchild A, King A, Gozar MM, Passioura T, Tucker C, Rivory L. Cytotoxic G-rich oligodeoxynucleotides: putative protein targets and required sequence motif. Nucleic Acids Res. 2007;35(13):4562–72.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Jing N, Li Y, Xiong W, Sha W, Jing L, Tweardy DJ. G-quartet oligonucleotides: a new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis. Cancer Res. 2004;64(18):6603–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Jing N, Zhu Q, Yuan P, Li Y, Mao L, Tweardy DJ. Targeting signal transducer and activator of transcription 3 with G-quartet oligonucleotides: a potential novel therapy for head and neck cancer. Mol Cancer Ther. 2006;5(2):279–86.CrossRefPubMedGoogle Scholar
  19. 19.
    Pedersen EB, Nielsen JT, Nielsen C, Filichev VV. Enhanced anti-HIV-1 activity of G-quadruplexes comprising locked nucleic acids and intercalating nucleic acids. Nucleic Acids Res. 2011;39(6):2470–81.CrossRefPubMedGoogle Scholar
  20. 20.
    Jing N, Hogan ME. Structure-activity of tetrad-forming oligonucleotides as a potent anti-HIV therapeutic drug. J Biol Chem. 1998;273(52):34992–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Zhi L, Zhang J, Jia Y, et al. Effect of G-rich oligonucleotides on the proliferation of leukemia cells and its relationship with p53 expression. Oligonucleotides. 2011;21(1):21–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Xu X, Hamhouyia F, Thomas SD, et al. Inhibition of DNA replication and induction of S phase cell cycle arrest by G-rich oligonucleotides. J Biol Chem. 2001;276(46):43221–30.CrossRefPubMedGoogle Scholar
  23. 23.
    Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol. 2009;86(3):151–64.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Weerasinghe P, Garcia GE, Zhu Q, et al. Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides. Int J Oncol. 2007;31(1):129–36.PubMedGoogle Scholar
  25. 25.
    Scaggiante B, Dapas B, Grassi G, Manzini G. Interaction of G-rich GT oligonucleotides with nuclear-associated eEF1A is correlated with their antiproliferative effect in haematopoietic human cancer cell lines. FEBS J. 2006;273(7):1350–61.CrossRefPubMedGoogle Scholar
  26. 26.
    Nonaka Y, Sode K, Ikebukuro K. Screening and improvement of an anti-VEGF DNA aptamer. Molecules. 2010;15(1):215–25.CrossRefPubMedGoogle Scholar
  27. 27.
    Patwardhan G, Gupta V, Huang J, Gu X, Liu YY. Direct assessment of P-glycoprotein efflux to determine tumor response to chemotherapy. Biochem Pharmacol. 2010;80(1):72–9.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Walsh N, Larkin A, Kennedy S, et al. Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma. BMC Urol. 2009;9:6.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Perez-Tomas R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem. 2006;13(16):1859–76.CrossRefPubMedGoogle Scholar
  30. 30.
    Tiwari AK, Sodani K, Dai CL, Ashby Jr CR, Chen ZS. Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol. 2011;12(4):570–94.CrossRefPubMedGoogle Scholar
  31. 31.
    Xing H, Wang S, Weng D, et al. Knock-down of P-glycoprotein reverses taxol resistance in ovarian cancer multicellular spheroids. Oncol Rep. 2007;17(1):117–22.PubMedGoogle Scholar
  32. 32.
    Liu FS. Mechanisms of chemotherapeutic drug resistance in cancer therapy—a quick review. Taiwan J Obstet Gynecol. 2009;48(3):239–44.CrossRefPubMedGoogle Scholar
  33. 33.
    Hille S, Rein DT, Riffelmann M, et al. Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer. Anti-Cancer Drugs. 2006;17(9):1041–4.CrossRefPubMedGoogle Scholar
  34. 34.
    Han Z, Feng J, Hong Z, et al. Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells. Biochem Biophys Res Commun. 2013;435(2):188–94.CrossRefPubMedGoogle Scholar
  35. 35.
    Shao CH, Rozanski GJ, Nagai R, et al. Carbonylation of myosin heavy chains in rat heart during diabetes. Biochem Pharmacol. 2010;80(2):205–17.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Kamazawa S, Kigawa J, Kanamori Y, et al. Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol Oncol. 2002;86(2):171–6.CrossRefPubMedGoogle Scholar
  37. 37.
    Penson RT, Oliva E, Skates SJ, et al. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol. 2004;93(1):98–106.CrossRefPubMedGoogle Scholar
  38. 38.
    Masanek U, Stammler G, Volm M. Modulation of multidrug resistance in human ovarian cancer cell lines by inhibition of P-glycoprotein 170 and PKC isoenzymes with antisense oligonucleotides. J Exp Ther Oncol. 2002;2(1):37–41.CrossRefPubMedGoogle Scholar
  39. 39.
    Jing N. Developing G-quartet oligonucleotides as novel anti-HIV agents: focus on anti-HIV drug design. Exp Opin Investig Drugs. 2000;9(8):1777–85.CrossRefGoogle Scholar
  40. 40.
    Gomez-Marquez J. DNA G-quadruplex: structure, function and human disease. FEBS J. 2010;277(17):3451.CrossRefPubMedGoogle Scholar
  41. 41.
    Soundararajan S, Chen W, Spicer EK, Courtenay-Luck N, Fernandes DJ. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res. 2008;68(7):2358–65.CrossRefPubMedGoogle Scholar
  42. 42.
    Teng Y, Girvan AC, Casson LK, et al. AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin. Cancer Res. 2007;67(21):10491–500.CrossRefPubMedGoogle Scholar
  43. 43.
    Weerasinghe P, Li Y, Guan Y, Zhang R, Tweardy DJ, Jing N. T40214/PEI complex: a potent therapeutics for prostate cancer that targets STAT3 signaling. Prostate. 2008;68(13):1430–42.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Tan B, Piwnica-Worms D, Ratner L. Multidrug resistance transporters and modulation. Curr Opin Oncol. 2000;12(5):450–8.CrossRefPubMedGoogle Scholar
  45. 45.
    Chen H, Landen CN, Li Y, Alvarez RD, Tollefsbol TO. Enhancement of cisplatin-mediated apoptosis in ovarian cancer cells through potentiating G2/M arrest and p21 upregulation by combinatorial epigallocatechin gallate and sulforaphane. J Oncol. 2013;2013:872957.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Park YT, Jeong JY, Lee MJ, et al. MicroRNAs overexpressed in ovarian ALDH1-positive cells are associated with chemoresistance. J Ovarian Res. 2013;6(1):18.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Mo QQ, Chen PB, Jin X, et al. Inhibition of Hec1 expression enhances the sensitivity of human ovarian cancer cells to paclitaxel. Acta Pharmacol Sin. 2013;34(4):541–8.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Watson J. Oxidants, antioxidants and the current incurability of metastatic cancers. Open Biol. 2013;3(1):120144.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Biao Wang
    • 1
  • Shuo Li
    • 1
  • Xin Meng
    • 1
  • Hong Shang
    • 2
  • Yifu Guan
    • 1
  1. 1.Department of Biochemistry and Molecular Biology, College of Basic Medical SciencesChina Medical UniversityShenyangPeople’s Republic of China
  2. 2.Department of Laboratory Medicine, the First Affiliated HospitalChina Medical UniversityShenyangChina

Personalised recommendations